Table 1.
Clinical characteristics of patients.
| Overall (N = 11) | |
|---|---|
| Age (years) | 59.2 ± 9.9 |
| Gender (male) | 9 (81.8%) |
| Height (cm) | 183.0 ± 3.9 |
| Weight (Kg) | 95.2 ± 12.7 |
| BMI | 29.4 ± 3.9 |
| CHA2DS2VASc | 1.8 ± 0.8 |
| Hypertension | 9 (81.8%) |
| Diabetes | 3 (27.3%) |
| Dyslipidemia | 6 (54.5%) |
| Heart failure | 1 (9.1%) |
| Chronic kidney disease | 2 (18.2%) |
| Coronary artery disease | 1 (9.1%) |
| Valvular heart disease | 0 (0.0%) |
| COPD | 1 (9.1%) |
| TIA or CVA | 0 (0.0%) |
| Drugs | |
| AAD Class Ic | 2 (18.2%) |
| Betablockers | 6 (54.5%) |
| AAD Class III | 4 (36.4%) |
| AAD Class IV | 0 (0.0%) |
| OAC | 11 (100.0%) |
| VKA | 0 (0.0%) |
| DOACs | 11 (100.0%) |
| Aspirin | 1 (9.1%) |
| ACEI or ARBs | 8 (2.7%) |
| LVEF (%) | 51.0 ± 16.4 |
| LA volume index (mL/mq) | 43.8 ± 12.0 |
AAD: antiarrhythmic drugs; BMI: body mass index; COPD: chronic obstructive pulmonary disease; CVA: cerebrovascular accident; DOACs: direct oral anticoagulants; LA: left atrium; LVEF: left ventricular ejection fraction; OAC: oral anticoagulation; TIA: transient ischemic attack; VKA: vitamin K antagonists.